Novo Nordisk is one of the world's leading producers of diabetes therapies including human insulin, insulin analogues, and injection devices. It makes modern insulin analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin), Victoza for type 2 diabetes, and Saxenda, which treats obesity. The firm also has products in the areas of hemostasis management (blood clotting), human growth hormone, and estrogen replacement therapy. The company has affiliates in some 80 countries and markets products in about 170 countries. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls the voting power in Novo Nordisk.
Financial data as of December 31, 2019 (12 month period) in USD
Dun & Bradstreet collects private company financials for more than 23 million companies in over 200 countries. Find out more.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
- EMPLOYEES (This Site) 1,000
- ASSETS (MIL USD) 18,596
- SALES (MIL USD) 18,063.99
- TICKER SYMBOL NOVO B
- FISCAL YEAR END DEC
- SALES GROWTH % 9.11%
- NET INCOME GROWTH 0.84%
Get in Touch with 2 Contacts
Lars Fruergaard JørgensenManaging Director
Stig StrøbækStaff representative on the board
Andreas Helmut FibigBoard Member
Martin William MackayBoard Member